Betamethasone
DIPROLENE
What it isPotent long-acting glucocorticoid; topical dermatoses and, antenatally, fetal lung maturation.
Why this oneIt resists placental inactivation, which is why it and dexamethasone are used antenatally rather than hydrocortisone.
What limits itTopical use can cause skin atrophy and striae; systemic exposure causes marked adrenal-axis suppression.
FDA-approved for
- corticosteroid-responsive dermatoses
FDA label
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Corticosteroid-responsive dermatoses | Adults | Thin film QD to affected area | Thin film QD (up to BID if needed) |
Renal Undefined
Hepatic Undefined
Instructions
- Apply thin film to affected skin
- Do not use with occlusive dressings
- Institute antimicrobial therapy if infection develops
Cautions
- Systemic absorption can cause reversible HPA-axis suppression, Cushing's syndrome, hyperglycemia, glucosuria
- Local skin atrophy, striae, secondary infection
Adverse reactions
- Burning, itching, irritation, dryness
- Folliculitis, hypertrichosis, acneiform eruptions
- Hypopigmentation, perioral dermatitis, allergic contact dermatitis
- Skin atrophy, striae, miliaria
Pregnancy Undefined
Lactation Undefined
NO BOXED WARNINGS
Principal riskSkin atrophy topically; axis suppression systemically
Cost, est. cash$30–$500/month
Generic entryPre-1982
Classes and tags
Clinical profile
Legacy pregnancy categoryC
Defining liabilityTremor, tachycardia or anticholinergic effects; excessive beta-agonist exposure can cause hypokalemia and arrhythmia.
Mechanism of action: Betamethasone ballicule
Open Betamethasone in the interactive console ↗
Memory aids: mascots and interaction avatars
